Randall Hamilton, MD
Neurology · Des Moines, IANPI 1518977412
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,137 of the $5,297 with a category attached, or 78.1%. It is spread thinly across 20 manufacturers, the largest accounting for just 22.8% — the pattern of someone who eats at a lot of different presentations.
Across 161 payments — averaging $32.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- AbbVie$879
- TG Therapeutics, Inc.$755
- Teva Pharmaceuticals USA, Inc.$569
- Adamas Pharmaceuticals, Inc.$346
- Biogen$275
- plus $1K from 14 others
Across 1 payment — averaging $870.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$870
What the payments were for
- Travel & lodging$82416%
- Food & beverage$4,13778%
- Education$3366%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 9 | $1,206 |
| AbbVie | 56 | $879 |
| TG Therapeutics, Inc. | 24 | $755 |
| Teva Pharmaceuticals USA, Inc. | 8 | $569 |
| Adamas Pharmaceuticals, Inc. | 24 | $346 |
| Biogen | 9 | $275 |
| EMD Serono, Inc. | 2 | $241 |
| Novartis | 10 | $171 |
| Genentech USA, Inc. | 2 | $166 |
| MDD US Operations, LLC | 3 | $155 |
| AstraZeneca | 1 | $107 |
| Johnson & Johnson | 1 | $104 |
| E.r. Squibb & Sons, L.L.C. | 1 | $82 |
| Pfizer | 3 | $59 |
| UCB, Inc. | 2 | $53 |
| SK Life Science, Inc. | 1 | $38 |
| Argenx US, Inc. | 1 | $31 |
| Sunovion Pharmaceuticals Inc. | 2 | $26 |
| Abbott | 1 | $20 |
| Lilly USA, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PERCEPT PC BRAINSENSE$989
- BRIUMVI$401
- Activase$144
- Austedo XR$137
- Xadago$126
- Vumerity$125
- ULTOMIRIS$107
How this compares
$5,297 in reported general payments places this provider in the 80th percentile of 132 neurology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 70 | $381,051 |
| IngrezzaValbenazine Tosylate | 34 | $254,992 |
| RytaryCarbidopa/Levodopa | 145 | $204,300 |
| GocovriAmantadine Hcl | 18 | $86,385 |
| Tetrabenazine | 13 | $71,605 |
| AustedoDeutetrabenazine | 12 | $57,401 |
| Nurtec OdtRimegepant Sulfate | 20 | $22,822 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 553 | $18,840 |
| Aimovig AutoinjectorErenumab-Aooe | 15 | $15,961 |
| HorizantGabapentin Enacarbil | 12 | $11,514 |
| Emgality PenGalcanezumab-Gnlm | 13 | $8,928 |
| NamzaricMemantine Hcl/Donepezil Hcl | 12 | $7,658 |
| Gabapentin | 129 | $3,351 |
| Primidone | 135 | $3,347 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 121 | $3,064 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MDD US Operations, LLCGocovri | $155 | $86,38518 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $569 | $57,40112 claims |
| PfizerNurtec Odt | $59 | $22,82220 claims |
| AbbVieNamzaric | $879 | $7,65812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 132 neurology providers in Iowa.
Other neurology in Des Moines
- Bruce HughesDes Moines$1.8M
- Michael JacobyDes Moines$243K
- Lynn RankinDes Moines$181K
- Wendy ZadehDes Moines$134K
- Paul BabikianDes Moines$107K
- Mark PuricelliDes Moines$45K
- Keith KohoutDes Moines$36K
- Erik ArnesonDes Moines$10K
- John WrightDes Moines$9K
- Lynn StruckDes Moines$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.